Anvisa approves Caplin point Chennai located sterile injectable site
Anvisa, Brazilian regulatory authority has recently approved Caplin point sterile injectable manufacturing site at Chennai. After approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) caplin now has access to Brazilian Pharmaceutical market. The approval grants access to the Company to register and market its products at the large and growing Brazilian Pharmaceutical market.
Chennai facility is capable of manufacturing Liquid lnjectables in Vials, Ampoules, Lyophilized Vials and Ophthalmic dosages. During the press release Caplin Point Laboratories said “The company has received approval from Brazil’s National Health Surveillance Agency Anvisa (Agencia Nacional de Vigilancia Sanitaria) for its sterile injectable manufacturing site at Chennai”. "The facility is capable of manufacturing liquid injectables in Vials, Ampoules, Lyophilized Vials and Opthalmic dosages, was also recently approved by EU-GMP in July" it added.